Alembic Ltd logo

Alembic Ltd

NSE: ALEMBICLTD BSE: 506235

₹113.47

-0.81 (0.71%)

Sun, 22 Nov 2026, 07:07 pm

mtf coin illustrationMTF 5xInvest in Alembic Ltd with 5x LeverageBuy with MTFpremium button ring illustration
Market Cap (in Cr)2916.53
PE Ratio8.21
Dividend2.11
Health TechnologyHealth Technology
Pharmaceuticals: MajorPharmaceuticals: Major
24.5K24.5K

Alembic Ltd Company History

1907

1907

  • Incorporated at Vadodara.

1938

1938

  • Authorised capital Rs 20 lakhs with 10,000 6 1/4% preference and 10,000 equity shares; issued 5,000 preference and all equity.

1942

1942

  • Issued 5,000 6% preference shares.

1944

1944

  • Increased authorised capital to Rs 50 lakhs with 30,000 shares; issued 3,000 equity shares in 3:10 proportion.

1946

1946

  • Issued 2,000 equity shares as rights at Rs 150 premium in 2:13 proportion.

1947

1947

  • Converted 5,000 unclassified shares to equity issued as rights at Rs 150 premium in 1:3 proportion.

1948

1948

  • Converted 5,000 unclassified shares to equity issued as bonus in 1:4 proportion.

1949

1949

  • Increased authorised capital to Rs 1 crore with 5,000 6% third preference and 45,000 unclassified shares.
  • Converted 7,000 unclassified shares to equity issued as bonus in 2:3 proportion.

1958

1958

  • Authorised capital Rs 10,000,000; issued and paid-up Rs 8,000,000 as at 31 December.

1959

1959

  • Offered 20,000 right equity shares at par in 1:4 proportion.

1961

1961

  • Offered 10,000 right equity shares at par in 1:1 proportion.

1962

1962

  • Issued 9,500 bonus equity shares in 1:10 proportion.
  • Offered 40,000 right equity shares at Rs 30 premium in 4:11 proportion.

1966

1966

  • Issued 48,167 bonus equity shares in 1:3 proportion in December.
  • Issued 12,278 equity shares to members of Alembic Distributors Ltd and Alembic Distributing Agency on merger.

1967

1967

  • High Courts sanctioned amalgamation of Alembic Distributors Ltd effective 1 January.

1968

1968

  • Issued 25,080 right equity shares at par in 5:41 proportion.

1971

1971

  • Issued 57,487 right equity shares at par in 1:5 proportion in March.

1977

1977

  • Converted 6 1/4% and 6% III preference shares to 9% redeemable from 1 Jan 1976.
  • Redeemed 5,000 5% preference shares at Rs 105 on 1 Jan.

1979

1979

  • Issued 75,000 secured debentures of Rs 100 each as rights.

1980

1980

  • Redeemed 1,000 preference shares on 1 Jan 1978, 1 Jan 1979, 1 Nov 1980, 1 Jan 1981, 1 Jan 1982, 1 Jan 1983.

1985

1985

  • Redeemed 2,000 preference shares.
  • Allotted 66,900 equity shares to Neomer Ltd shareholders on merger.

1986

1986

  • High Court of Gujarat approved Neomer Ltd amalgamation effective 1 January 1983.

1989

1989

  • Introduced Feed Supplements and Tonics products.
  • Started Panpharm Division at Panelav, Gujarat for formulations.

1990

1990

  • Introduced Ciprofloxacin.
  • Veterinary division introduced ascal, ruman bolus and other products.
  • Introduced ginseng, zinc and vitamin-B complex preparations.
  • Issued 100,000 14% non-convertible debentures redeemable from 1995.

1991

1991

  • Developed Roxithromycin bulk drug.

1992

1992

  • Introduced Cloxacillin Amoxicillin injections in veterinary division.

1993

1993

  • Expanded Penicillin capacity to 1000 MMU with effluent treatment plant and diesel compressors.
  • Introduced Azithromycin antibiotic.

1995

1995

  • Proposed gas turbine captive co-generation power unit at Rs 25 crores.
  • Installed two large penicillin fermentors.
  • Issued 164,732 equity shares at Rs 850 premium on rights basis.

1996

1996

  • Allotted 1,000,000 preference shares on preferential basis.

1997

1997

  • Introduced Nimegesic Gel.
  • Introduced Rorid Roxithromycin liquid for paediatric use.
  • Launched Clarithro and basic manufacture of clarithromycin.
  • Installed Penicillin 600 MMU/annum and Erythromycin 100 TPA capacities with second extraction facility.
  • Launched Alembic Herbals veterinary division.
  • Issued 1,000,000 16% redeemable non-convertible cumulative preference shares.
  • Launched Rofecoxib and Celecoxib.

2000

2000

  • Launched Glycodin Activ Cold & Flu Tablets.

2001

2001

  • Launched 'Asigra' sildenafil citrate in 25 mg and 50 mg dosages.
  • Launched OTC Glycodin Activ cold and flu tablets.

2002

2002

  • Gujarat High Court sanctioned merger of Darshak Ltd Bulk Drug unit.
  • Entered in-licensing pact with Euroresearch for Gelfix Collagen dressing sponge pads.
  • Appointed Nitin Jaywant as President, Active Pharmaceutical Ingredients division.
  • Launched 'SynX' division for Syndrome X.
  • Entered research pact with Chiron Corporation.
  • Received DCGI approval for Cefetamet Pivoxil tablets.
  • Tied up with Euroresearch for product introduction in India.

2003

2003

  • Launched Cefepime, 4th generation injectable Cephalosporin.
  • Allotted equity shares to Darshak Ltd shareholders per demerger scheme.
  • Acquired brand and trademark rights of Yutopar from Solvay Pharmaceuticals.
  • Launched BioArc Research Solutions for R&D services.
  • Entered speciality therapeutics segment.
  • Signed R&D agreements with two MNC companies.
  • Announced rights issue of Rs 32.37 crores.
  • Raised Rs 10 crore through 90-day commercial paper.
  • Signed MoU with Xechem International.

2005

2005

  • Launched no-calorie sugar substitute 'Zero'.

2006

2006

  • Split face value of shares from Rs 10 to Rs 2.

2008

2008

  • Acquired API manufacturing unit of Nirayu Pvt Ltd at Panelav, Gujarat.

2009

2009

  • Recommended 20% dividend.

2010

2010

  • Appointed Milin Mehta as Additional Independent Director.

2011

2011

  • Appointed Ashok Tulankar as Vice President - Production, Additional Director and Whole-Time Director.

2012

2012

  • Appointed Chandrashekhar P. Buch as Additional Non-Executive Independent Director.

2013

2013

  • Allotted 13,35,15,914 bonus equity shares in 1:1 ratio.
  • Appointed R. C. Saxena as Additional Non-Executive Independent Director.
  • Recommended dividend of Re. 0.20 (10%) per equity share of Rs. 2.

2014

2014

  • Recommended dividend of Re. 0.15 (7.5%) per equity share of Rs. 2.

2018

2018

  • HGS won NASSCOM Customer Service Excellence Award 2018 in Transformation Category.

2020

2020

  • Received USFDA approval for generic ophthalmic solution.
pocketful logo lightpocketful logo dark
PricingBecome a Partner
search icon
/

No results for ''

Popular search

  • popular search iconSuzlon Energy Ltd
  • popular search iconIndian Railway Finance Corporation Ltd
  • popular search iconTata Motors Ltd
  • popular search iconTata Steel Ltd
  • popular search iconRail Vikas Nigam Ltd

Recent search

      Log In
      search icon

      No results for ‘’

        Popular search

        • popular search iconSuzlon Energy Ltd
        • popular search iconIndian Railway Finance Corporation Ltd
        • popular search iconTata Motors Ltd
        • popular search iconTata Steel Ltd
        • popular search iconRail Vikas Nigam Ltd
        • popular search iconReliance Industries Ltd
        pocketful logo lightpocketful logo dark
        • Pricing
        • Become a Partner
        Log In
        • home icon
        • arrow iconstocks
        • arrow iconalembic ltd
        • arrow iconhistory
        • Overview
        • Financials
        • Ratios
        • shareholding
        • Technical Analysis
        • Corporate Actions
        • Peer Comparison
        • About
        • Company History
        • Deals
        • News
        • FAQs

        Open Your Free Demat Account Now!

        Step into a world of zero fees and limitless opportunities!

        pocketful logo
        • Quick Links

          • Open Demat Account
          • Pocketful Web
          • Pocketful App
          • Pricing
          • Authorised Person
          • Pocketful Calculators
          • Compliance Links
        • Pages

          • Tools
          • Blogs
          • ETF Screener
          • IPO
          • ETF
          • Bonds
          • Index Heat Map
        • Products

          • Stocks
          • Commodity
          • Subscription
          • Free Stock Screener
          • Pocketful GPT
          • MTF
          • Mutual Funds
        • Company

          • About us
          • Contact us
          • Terms and Conditions
          • Policies & Procedures
          • Privacy Policy
          • Disclosure
          • Careers
        • Socials

          • Facebook iconFacebook
          • Twitter iconTwitter
          • Instagram iconInstagram
          • LinkedIn iconLinkedIn
          • Youtube iconYoutube

        2022-25 Pocketful. All rights reserved, Built with in India

        Version -5.76

        app image 1app image 2

        Stocks:

        AllABCDEFGHIJKLMNOPQRSTUVWXYZ

        Explore

        Calculators
        Popular Calculators
        Group Stocks
        Asset Management Companies
        Popular Stocks
        Indian Indices
        Sector Wise Stocks
        IPO
        Share Market
        Best MF Schemes
        Platforms
        Resources
        Gold Rates in Top Cities
        Silver Rates in Top Cities

        Others:

        NSEBSECDSLNSDLSEBIMCXMSEINCDEXNSE IFSCINDIA INXAccount Closure FormDP Investor CharterBroker Investor Charter

        Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800